StemCyte International, Ltd. (TPEX:4178)

Market Cap	5.21B -28.0%
Revenue (ttm)	385.12M +3.8%
Net Income	-187.63M
EPS	-0.94
Shares Out	192.24M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	315,408
Average Volume	245,171
Open	26.70
Previous Close	26.60
Day's Range	26.60 - 28.55
52-Week Range	20.50 - 37.40
Beta	n/a
RSI	36.36
Earnings Date	Apr 29, 2026

About StemCyte International

StemCyte International, Ltd., a biotechnology company, develops cord blood–based cell therapies in the United States and Taiwan. The company engages in the research and development of biotechnology and cell-based new drugs; supply of cellular materials; and operation of cord blood cell banks. It also offers umbilical cord blood transplantation and storage services; and cell products and services. In addition, the company provides REGENECYTE, an allogeneic umbilical cord blood cellular biotherapy for the treatment of cancer, hematological disord...

• Industry: Miscellaneous Health And Allied Services, Not Elsewhere Classified
• Founded: 1997
• Country: Cayman Islands
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4178

Financial Performance

In 2024, StemCyte International's revenue was 382.69 million, an increase of 5.49% compared to the previous year's 362.78 million. Losses were -205.66 million, -35.68% less than in 2023.